144 related articles for article (PubMed ID: 24790523)
1. DDIT3 Expression in Liposarcoma Development.
Kåbjörn Gustafsson C; Engström K; Aman P
Sarcoma; 2014; 2014():954671. PubMed ID: 24790523
[TBL] [Abstract][Full Text] [Related]
2. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
[TBL] [Abstract][Full Text] [Related]
3. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
[TBL] [Abstract][Full Text] [Related]
4. Lipomatous tumors.
Weiss SW
Monogr Pathol; 1996; 38():207-39. PubMed ID: 8744279
[TBL] [Abstract][Full Text] [Related]
5. DDIT3 Immunohistochemistry Is a Useful Tool for the Diagnosis of Myxoid Liposarcoma.
Scapa JV; Cloutier JM; Raghavan SS; Peters-Schulze G; Varma S; Charville GW
Am J Surg Pathol; 2021 Feb; 45(2):230-239. PubMed ID: 32815829
[TBL] [Abstract][Full Text] [Related]
6. Extensive lipoma-like changes of myxoid liposarcoma: morphologic, immunohistochemical, and molecular cytogenetic analyses.
Iwasaki H; Ishiguro M; Nishio J; Aoki M; Yokoyama R; Yokoyama K; Taguchi K; Nabeshima K
Virchows Arch; 2015 Apr; 466(4):453-64. PubMed ID: 25650275
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.
Thway K; Flora R; Shah C; Olmos D; Fisher C
Am J Surg Pathol; 2012 Mar; 36(3):462-9. PubMed ID: 22301498
[TBL] [Abstract][Full Text] [Related]
8. Liposarcoma With Hibernoma-like Histology: A Clinicopathologic Study of 16 Cases.
Kojima N; Komiyama M; Shinoda Y; Watanabe SI; Yatabe Y; Kawai A; Yoshida A
Am J Surg Pathol; 2022 Oct; 46(10):1319-1328. PubMed ID: 35475774
[TBL] [Abstract][Full Text] [Related]
9. Liposarcomas of the mediastinum.
Suster DI; Suster S
Mediastinum; 2020; 4():27. PubMed ID: 35118295
[TBL] [Abstract][Full Text] [Related]
10. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
Göransson M; Andersson MK; Forni C; Ståhlberg A; Andersson C; Olofsson A; Mantovani R; Aman P
Oncogene; 2009 Jan; 28(2):270-8. PubMed ID: 18850010
[TBL] [Abstract][Full Text] [Related]
11. Amplification of DNA damage-inducible transcript 3 (DDIT3) is associated with myxoid liposarcoma-like morphology and homologous lipoblastic differentiation in dedifferentiated liposarcoma.
Mantilla JG; Ricciotti RW; Chen EY; Liu YJ; Hoch BL
Mod Pathol; 2019 Apr; 32(4):585-592. PubMed ID: 30420727
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Value of MDM2 and DDIT3 Fluorescence In Situ Hybridization in Liposarcoma Classification: A Single-Institution Experience.
Cho J; Lee SE; Choi YL
Korean J Pathol; 2012 Apr; 46(2):115-22. PubMed ID: 23109990
[TBL] [Abstract][Full Text] [Related]
13. Myxoid liposarcoma with nuclear pleomorphism: a clinicopathological and molecular study.
Kojima N; Kubo T; Mori T; Satomi K; Matsushita Y; Iwata S; Yatabe Y; Ichimura K; Kawai A; Ichikawa H; Yoshida A
Virchows Arch; 2024 Jan; 484(1):71-81. PubMed ID: 37704823
[TBL] [Abstract][Full Text] [Related]
14. Cell senescence in myxoid/round cell liposarcoma.
Kåbjörn Gustafsson C; Ståhlberg A; Engtröm K; Danielsson A; Turesson I; Aman P
Sarcoma; 2014; 2014():208786. PubMed ID: 25093008
[TBL] [Abstract][Full Text] [Related]
15. Restoration of C/EBPα in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis.
Wu YV; Okada T; DeCarolis P; Socci N; O'Connor R; Geha RC; Joy Somberg C; Antonescu C; Singer S
Genes Chromosomes Cancer; 2012 Apr; 51(4):313-27. PubMed ID: 22170698
[TBL] [Abstract][Full Text] [Related]
16. Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma.
Berthold R; Isfort I; Erkut C; Heinst L; Grünewald I; Wardelmann E; Kindler T; Åman P; Grünewald TGP; Cidre-Aranaz F; Trautmann M; Fröhling S; Scholl C; Hartmann W
Oncogenesis; 2022 Apr; 11(1):20. PubMed ID: 35459264
[TBL] [Abstract][Full Text] [Related]
17. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma--assay validation and clinical experience.
Narendra S; Valente A; Tull J; Zhang S
Diagn Mol Pathol; 2011 Dec; 20(4):218-24. PubMed ID: 22089349
[TBL] [Abstract][Full Text] [Related]
18. Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma.
Ståhlberg A; Kåbjörn Gustafsson C; Engtröm K; Thomsen C; Dolatabadi S; Jonasson E; Li CY; Ruff D; Chen SM; Åman P
PLoS One; 2014; 9(11):e113110. PubMed ID: 25393000
[TBL] [Abstract][Full Text] [Related]
19. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.
Alaggio R; Coffin CM; Weiss SW; Bridge JA; Issakov J; Oliveira AM; Folpe AL
Am J Surg Pathol; 2009 May; 33(5):645-58. PubMed ID: 19194281
[TBL] [Abstract][Full Text] [Related]
20. SRC inhibition represents a potential therapeutic strategy in liposarcoma.
Sievers E; Trautmann M; Kindler D; Huss S; Gruenewald I; Dirksen U; Renner M; Mechtersheimer G; Pedeutour F; Åman P; Nishio J; Schildhaus HU; Kirfel J; Schirmacher P; Wardelmann E; Buettner R; Hartmann W
Int J Cancer; 2015 Dec; 137(11):2578-88. PubMed ID: 26084847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
